Uncategorized
Collaboration to advance precision oncology therapy
Oncology company One-carbon Therapeutics has entered a strategic collaboration with precision medicine company Tempus AI to advance precision oncology development.
The collaboration will leverage Tempus’ proprietary, de-identified multimodal database and bioinformatics knowledge to advance molecular insights supporting the clinical development of TH9619.
TH9619, developed by One-carbon Therapeutics, is a first-in-class, potent small-molecule inhibitor of overexpressed enzymes MTHFD1 and MTHFD2. This inhibition in cancer cells induces toxic folate trapping, starving tumours of the critical DNA building block thymidine, leading to DNA damage and causing cancer cell death.
As part of the collaboration, One-carbon Therapeutics will use Tempus’ analytical services to characterise the expression landscape across prioritised solid tumour indications. By integrating RNA sequencing data with clinical variables, the teams aim to uncover molecular insights to develop TH9619.
“Understanding the molecular dynamics of one-carbon metabolism across tumour types and treatment settings is fundamental to advancing TH9619 with precision,” said Ana Slipicevic, Chief Executive Officer at One-carbon Therapeutics.
“Tempus’ depth of molecular data and analytical rigour enables us to generate statistically robust evidence that can potentially guide clinical decision making and optimise development.”
“At Tempus, our goal is to accelerate progress in oncology by translating complex molecular insights into meaningful therapeutic advances,” said Ezra Cohen, Chief Medical Officer, Oncology, at Tempus.
“Through comprehensive analysis of our multimodal dataset, we are supporting One-carbon Therapeutics in characterising the metabolic signatures across diverse tumour types. These insights are essential to informing research strategies and advancing the development of next-generation targeted cancer therapies.”
The post Collaboration to advance precision oncology therapy appeared first on Drug Discovery World (DDW).
The acquisition of Tubulis GmbH—Gilead Sciences’ latest of the year after buying Arcells and Ouro Medicines—brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-stage data.
Uncategorized
STAT+: Pharmalittle: We’re reading about FDA backing domestic production, another Gilead deal, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where clear blue skies and comfortable breezes are greeting us. Who could ask for anything more? Actually, we could — it is time to reheat the kettle for another cuppa stimulation. Our choice today is ginger peach. And here is a helpful tip — a teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are now hawking replicas — take a look. Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips. …
The U.S. Food and Drug Administration used the president’s budget to propose policies aimed at encouraging domestic development and manufacturing of drugs, STAT notes. FDA Commissioner Marty Makary has said the agency needs “giant, big ideas” to counter China’s dominance in early-stage clinical development of drugs. Among the FDA’s ideas are proposals to make it easier to run early-stage trials in the U.S. and to hand an advantage to U.S.-based generics manufacturers. The Trump administration has been using a variety of policy levers to try and bring drug manufacturing to the U.S. One of the legislative proposals in the FDA’s budget justification would let domestic manufacturers of generic drugs challenge brand drug patents a month before foreign companies, a major advantage in an intensely competitive process.
Two more drugmakers, AbbVie and Genentech, will officially start selling their medicines on the TrumpRx website, CBS News tells us. Abbvie, which struck a deal with the Trump administration in January to cut the cost of certain medicines, will sell Humira, a popular medication used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, on the site at an 86% discount. The prescription prices on the site, however, are only available to patients who are uninsured, or whose insurance does not cover it, and who must pay the full list price out of pocket. Those with insurance coverage generally pay lower prices already. TrumpRx now sells over 61 drugs at a lower price, up from about 40 when the website went live in February.
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where clear blue skies and comfortable breezes are greeting us. Who could ask for anything more? Actually, we could — it is time to reheat the kettle for another cuppa stimulation. Our choice today is ginger peach. And here is a helpful tip — a teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are now hawking replicas — take a look. Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips. …
The U.S. Food and Drug Administration used the president’s budget to propose policies aimed at encouraging domestic development and manufacturing of drugs, STAT notes. FDA Commissioner Marty Makary has said the agency needs “giant, big ideas” to counter China’s dominance in early-stage clinical development of drugs. Among the FDA’s ideas are proposals to make it easier to run early-stage trials in the U.S. and to hand an advantage to U.S.-based generics manufacturers. The Trump administration has been using a variety of policy levers to try and bring drug manufacturing to the U.S. One of the legislative proposals in the FDA’s budget justification would let domestic manufacturers of generic drugs challenge brand drug patents a month before foreign companies, a major advantage in an intensely competitive process.
Two more drugmakers, AbbVie and Genentech, will officially start selling their medicines on the TrumpRx website, CBS News tells us. Abbvie, which struck a deal with the Trump administration in January to cut the cost of certain medicines, will sell Humira, a popular medication used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, on the site at an 86% discount. The prescription prices on the site, however, are only available to patients who are uninsured, or whose insurance does not cover it, and who must pay the full list price out of pocket. Those with insurance coverage generally pay lower prices already. TrumpRx now sells over 61 drugs at a lower price, up from about 40 when the website went live in February.
Uncategorized
FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes
FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes
Aiming to protect patients, the FDA sent lawmakers a wish list of legislative proposals intended to clarify and expand its oversight of updates to approved drug production processes. Read More
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
STAT+: Pharmalittle: We’re reading about FDA backing domestic production, another Gilead deal, and more
FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
STAT+: Gilead to buy cancer biotech Tubulis for more than $3 billion
Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years ago
The final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years ago
According to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years ago
The old and New Edition cast comes together to perform
-
Uncategorized9 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years ago
Uber and Lyft are finally available in all of New York State
-
Uncategorized9 years ago
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years ago
Steph Curry finally got the contract he deserves from the Warriors